Article source：
Sep 22,2026
View：
30 Recently, Kexing Biopharm’s international product Paclitaxel for Injection (Albumin-Bound) (Apexelsin®) successfully passed the review by the Drug Safety Center of the Ministry of Health of the Republic of Uzbekistan and received its drug registration certificate, marking another important milestone in the company’s internationalization.
Uzbekistan is the most populous country in Central Asia, with a population of approximately 38.38 million as of April 2026, accounting for around 45% of the total population of Central Asia. As an important country participating in the Belt and Road Initiative, Uzbekistan has also become an increasingly significant market for the pharmaceutical industry. According to media reports, the country’s pharmaceutical and medical device market is approaching US$2.5 billion, making it one of the larger pharmaceutical markets in Central Asia.
In recent years, Kexing Biopharm has continued to strengthen its internationalization strategy and has developed comprehensive capabilities covering the entire overseas commercialization process, including international market research, regulatory registration, and marketing and promotion.
Apexelsin®, Kexing Biopharm’s albumin-bound paclitaxel product, received marketing authorization from the European Commission in 2024. Since then, its international commercialization has progressed rapidly, with the product having obtained marketing approvals in more than 40 countries and regions to date.
Looking ahead, Kexing Biopharm will continue to accelerate the global commercialization of more high-quality pharmaceutical products, making innovative and reliable medicines available to patients in more countries and regions around the world.
BACK TO LIST
Aug 11,2026
